Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Kamada, Yoshihiro ^a   Akita, Maaya ^a   Takeda, Yuri ^a   Yamada, Shin ^b   Fujii, Hideki ^c   Sawai, Yoshiyuki ^d   Doi, Yoshinori ^e   Asazawa, Hitomi ^a   Nakayama, Kotarosumitomo ^a   Mizutani, Kayo ^a   Fujii, Hironobu ^a   Yakushijin, Takayuki ^a   Miyazaki, Masanori ^a   Ezaki, Hisao ^a   Hiramatsu, Naoki ^a   Yoshida, Yuichi ^a   Kiso, Shinichi ^a   Imai, Yasuharu ^d   Kawada, Norifumi ^c   Takehara, Tetsuo ^a   Miyoshi, Eiji ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Otani Clinic   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Ikeda Municipal Hospital   (Japan)

^e OTEMAE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FUCOSYLATED HAPTOGLOBIN; HAPTOGLOBIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HP PROTEIN, HUMAN;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BALLOONING HEPATOCYTE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; ECHOGRAPHY; ELISA KIT; FEMALE; FIB 4 INDEX; HEPATITIS C; HEPATOCYTE BALLOONING SCORE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PATIENT MONITORING; PREDICTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; BLOOD; CLINICAL TRIAL; LIVER CELL; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ADULT; AGE FACTORS; AGED; BIOMARKERS; FEMALE; HAPTOGLOBINS; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84879260527     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066328     Document Type: Article

References (44)

1. Ford ES, Giles WH, Dietz WH, (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356-359.
2. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134-140.
3. Wanless IR, Lentz JS, (1990) Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12: 1106-1110.
4. Neuschwander-Tetri BA, Caldwell SH, (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219.
5. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395.
6. Angulo P, (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231.
7. Liou I, Kowdley KV, (2006) Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 40Suppl 1: S11-16.
8. Piccinino F, Sagnelli E, Pasquale G, Giusti G, (1986) Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 2: 165-173.
9. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898-1906.
10. Ohtsubo K, Marth JD, (2006) Glycosylation in cellular mechanisms of health and disease. Cell 126: 855-867.
11. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, et al. (2004) Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10: 429-434.
12. Ito K, Kuno A, Ikehara Y, Sugiyama M, Saito H, et al. (2012) LecT-hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology 56: 1448-1456.
13. Miyoshi E, Moriwaki K, Nakagawa T, (2008) Biological function of fucosylation in cancer biology. J Biochem 143: 725-729.
14. Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, et al. (2004) alpha1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 101: 2825-2836.
15. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, et al. (2009) Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 18: 1914-1921.
16. Okuyama N, Ide Y, Nakano M, Nakagawa T, Yamanaka K, et al. (2006) Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 118: 2803-2808.
17. Nakano M, Nakagawa T, Ito T, Kitada T, Hijioka T, et al. (2008) Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 122: 2301-2309.
18. Takeda Y, Shinzaki S, Okudo K, Moriwaki K, Murata K, et al. (2011) Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Cancer.
19. Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, Nakagawa T, et al. (2008) Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem Biophys Res Commun 377: 792-796.
20. Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, et al. (2006) Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem 281: 29797-29806.
21. Lefkowitch JH, (2005) Morphology of alcoholic liver disease. Clin Liver Dis 9: 37-53.
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
23. Brunt EM, Tiniakos DG, (2010) Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 16: 5286-5296.
24. Yoon Y, Torok N, Krueger E, Oswald B, McNiven MA, (1998) Ethanol-induced alterations of the microtubule cytoskeleton in hepatocytes. Am J Physiol 274: G757-766.
25. Chambers W, Thompson S, Skillen AW, Record CO, Turner GA, (1993) Abnormally fucosylated haptoglobin as a marker for alcoholic liver disease but not excessive alcohol consumption or non-alcoholic liver disease. Clin Chim Acta 219: 177-182.
26. Sanyal AJ, (2002) AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123: 1705-1725.
27. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, et al. (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43: 1317-1325.
28. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, et al. (2009) Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7: 1104-1112.
29. Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, et al. (2012) Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 12: 2.
30. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413-1419.
31. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, et al. (2011) Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53: 1874-1882.
32. Lackner C, (2011) Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective. Expert Rev Gastroenterol Hepatol 5: 223-231.
33. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, et al. (2006) In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44: 27-33.
34. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, et al. (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50: 1072-1078.
35. Przybylo M, Martuszewska D, Pochec E, Hoja-Lukowicz D, Litynska A, (2007) Identification of proteins bearing beta1-6 branched N-glycans in human melanoma cell lines from different progression stages by tandem mass spectrometry analysis. Biochim Biophys Acta 1770: 1427-1435.
36. Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, et al. (2004) 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 19: 551-556.
37. Nonaka M, Ma BY, Imaeda H, Kawabe K, Kawasaki N, et al. (2011) Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J Biol Chem 286: 22403-22413.
38. Nakagawa T, Moriwaki K, Terao N, Miyamoto Y, Kamada Y, et al. (2012) Analysis of Polarized Secretion of Fucosylated Alpha-Fetoprotein in HepG2 Cells. J Proteome Res.
39. Kitagawa Y, Sano Y, Ueda M, Higashio K, Narita H, et al. (1994) N-glycosylation of erythropoietin is critical for apical secretion by Madin-Darby canine kidney cells. Exp Cell Res 213: 449-457.
40. Kuno A, Ikehara Y, Tanaka Y, Angata T, Unno S, et al. (2011) Multilectin assay for detecting fibrosis-specific glyco-alteration by means of lectin microarray. Clin Chem 57: 48-56.
41. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, et al. (1998) Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 11: 560-565.
42. Gawrieh S, Knoedler DM, Saeian K, Wallace JR, Komorowski RA, (2011) Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. Ann Diagn Pathol 15: 19-24.
43. Juluri R, Vuppalanchi R, Olson J, Unalp A, Van Natta ML, et al. (2011) Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol 45: 55-58.
44. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, et al. (2008) Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 48: 821-828.